Iovance Biotherapeutics is a biotechnology business based in the US. Iovance Biotherapeutics shares (IOVA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.50 – a decrease of 3.05% over the previous week. Iovance Biotherapeutics employs 838 staff and has a trailing 12-month revenue of around $164.1 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $3.50 |
|---|---|
| 52-week range | $2.70 - $14.13 |
| 50-day moving average | $3.68 |
| 200-day moving average | $7.48 |
| Wall St. target price | $20.08 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.28 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.5 from 2025-05-02
| 1 week (2025-04-28) | -3.05% |
|---|---|
| 1 month (2025-04-04) | 16.67% |
| 3 months (2025-02-06) | -40.48% |
| 6 months (2024-11-06) | -71.17% |
| 1 year (2024-05-06) | -74.78% |
|---|---|
| 2 years (2023-05-05) | -48.91% |
| 3 years (2022-05-05) | 14.83 |
| 5 years (2020-05-05) | 32.66 |
| Revenue TTM | $164.1 million |
|---|---|
| Gross profit TTM | $40.1 million |
| Return on assets TTM | -29.22% |
| Return on equity TTM | -57.48% |
| Profit margin | -226.84% |
| Book value | $2.33 |
| Market Capitalization | $1.2 billion |
TTM: trailing 12 months
We're not expecting Iovance Biotherapeutics to pay a dividend over the next 12 months.
Iovance Biotherapeutics's shares were split on a 1:100 basis on 25 September 2013 . So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Iovance Biotherapeutics shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Iovance Biotherapeutics shares which in turn could have impacted Iovance Biotherapeutics's share price.
Over the last 12 months, Iovance Biotherapeutics's shares have ranged in value from as little as $2.7 up to $14.13. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Iovance Biotherapeutics's is 1.045. This would suggest that Iovance Biotherapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Iovance Biotherapeutics, Inc. , a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops lifileucel for treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001, an antibody cytokine engrafted protein for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc. ; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .